In November 2020, the U.S. Department of Defense awarded a contract to Puritan Medical Products to increase the domestic production capacity of nasal swabs.



  • 1 harmful
  • 0 neutral
  • 0 liberalising


U.S. Department of Defense, Releases, “DOD Awards $11.6 Million to Puritan Medical Products Company, LLC to Increase Domestic Production of Swabs for Cue Health's Point of Care Tests”. Available at:

Inception date: 19 Nov 2020 | Removal date: open ended

State aid, unspecified

On 19 November 2020, the U.S. Department of Defense (DOD) awarded a USD 11.6 million contract to Puritan Medical Products Company, LLC, to increase the domestic manufacturing capability of nasal swabs. Puritan Medical will produce these nasal swabs for Cue Health’s molecular in vitro diagnostic test that aids in the detection and diagnosis of COVID-19. With this award, Puritan Medical will accelerate the implementation of facility upgrades and will reach a production capacity of 3 million nasal swabs per month by March 2021. With this award, DOD aims to support the domestic supply chain of COVID-10 testing.

This effort is led by DOD’s Defense Assisted Acquisition Cell, and funded through the Health Care Enhancement Act (HCEA) to support domestic industrial base expansion for critical medical resources.

To strengthen the United States’ supply chain resilience and manufacturing capacity, and to address supply chain vulnerabilities, the U.S. DOD provides funding to support the production and supply of critical materials and goods. DOD funding can in various forms. The present award didn’t specify the intervention type, hence, ‘state-aid, unspecified’ is selected as the intervention type.